摘要
目的探析在超声引导下经6点和12点行前列腺定位穿刺活检术诊断前列腺癌的临床价值。方法选取我院2013年7月至2014年7月收治的疑是前列腺癌患者92例,均采用超声引导下经直肠6点前列腺定位活检穿刺进行诊断,并将其作为对照组,观察组联合12点定位活检穿刺,比较两组检出率,观察两组的并发症。结果经病理诊断发现,92例患者中前列腺癌患者53例(57.6%),前列腺增生患者25例(27.2%),前列腺炎患者14例(15.2%)。观察组前列腺癌检出率为100.0%(53/53),显著高于对照组的77.4%(41/53),差异具有统计学意义(P<0.05),单纯6点定位活检漏诊率为22.6%(12/53)。观察组血尿率、血便率、血精率、肛门滴血率和发热率与对照组相比均无显著差异(P>0.05)。两组均未见高热、前列腺脓肿和败血症等严重不良反应。结论在超声引导下经6点、12点行前列腺定位穿刺活检术诊断前列腺癌可有效提高检出率,且不增加并发症。
Objective To discuss the clinical value of prostate biopsy location per rectum 6 and 12 points in the diagnosis of prostate cancer guided by ultrasound. Methods 92 patients with suspected prostate cancer treated in our hospital from July 2013 to July 2014 were selected as objects. All the patients were given prostate biopsy location per rectum 6 points guided by ultrasound and chosen as control group, the observation group was given prostate biopsy location per rectum 6 points combined with 12 points guided by ultrasound. The detection rates and complications of the two groups were compared and observed. Results Among 92 patients, 53 patients (57.6%) were diagnosed out prostate cancer, 25 patients (27.2%) were diagnosed out benign prostatic hyperplasia and 14 patients (15.2%) were diagnosed out prostatitis. The detection rate of prostate cancer of the observation group was 100.0% (53/53), obviously higher than 77.4% (41/53) of the control group (P 〈0.05), and the misdiagnosis rate of the control group was 22.6% (12/53). The hematuresis rate, the bloody stools rate, the hematospermia rate, the anus drop of blood rate and the fever rate of the two groups had no statistical significant difference (all P 〉0.05). No severe adverse reactions were found in the two groups. Conclusions Prostate biopsy location per rectum 6 and 12 points guided by ultrasound in diagnosis of prostate cancer can effectively improve the detection rate without increasing complications.
出处
《临床医学工程》
2014年第12期1523-1524,1534,共3页
Clinical Medicine & Engineering
关键词
超声引导
直肠穿刺
前列腺活检术
前列腺癌
Ultrasound-guided
Per rectum puncture
Prostate biopsy
Prostate cancer